Sanofi has agreed to acquire Blueprint Medicines for $9.1 billion, expanding its footprint in rare immunological diseases.

With the deal, Sanofi gains Blueprint’s portfolio of rare immunological disease treatments, including systemic mastocytosis ...

The deal includes a drug approved in the U.S. and the EU for systemic mastocytosis, a rare immunology disease, as well as an ...

The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

Sanofi's $470M Vigil Neuroscience, Inc. acquisition highlights VG-3927's potential in Alzheimer's. Click here to find out why ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in ...

French drugmaker Sanofi said Monday it has agreed to acquire Blueprint Medicines for $9.5 billion, sending shares of the ...

Sanofi announced that it will buy pharma company Blueprint Medicines for $129 per share, making the deal worth more than $9 ...

The French drugmaker will pay up to $9.5 bln for Blueprint Medicines, whose key product fights skin rashes. It eases CEO Paul ...

The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost ...

The new version of Sarclisa stems from a collaboration with Enable Injections, backed financially to the tune of €300 million ...